We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Therapy Cures Nicotine Addiction in Mouse Model

By LabMedica International staff writers
Posted on 10 Jul 2012
A novel gene-therapy approach has been used to treat nicotine addiction in a mouse model that mimics chronic cigarette smoking in humans.

Addiction to the nicotine in cigarette smoke prevents many smokers from quitting. More...
To overcome this addiction investigators at Weill Cornell Medical College (New York, NY, USA) developed a genetics-based vaccine. They incorporated the gene for an antinicotine monoclonal antibody into an adeno-associated virus (AAV). The vector, which expressed the gene for a full-length, high-affinity, antinicotine antibody derived from the Fab fragment of the antinicotine monoclonal antibody NIC9D9 was designed to infect liver cells and then manufacture the antibody.

The vector was administered to a population of laboratory mice. Results published in the June 27, 2012, online edition of the journal Science Translational Medicine revealed that in the treated mice blood concentrations of the antinicotine antibody were dose-dependent, and the antibody showed high specificity and affinity for nicotine. The antibody shielded the brain from systemically administered nicotine, reducing brain nicotine concentrations to 15% of those in control mice. The amount of nicotine sequestered in the serum of vector-treated mice was more than seven times greater than that in untreated mice, with 83% of serum nicotine bound to immunoglobulin G. Treatment with the vector blocked nicotine-mediated alterations in arterial blood pressure, heart rate, and locomotor activity.

"Our vaccine allows the body to make its own monoclonal antibodies against nicotine, and in that way, develop a workable immunity," said senior author Dr. Ronald G. Crystal, professor of genetic medicine at Weill Cornell Medical College." As far as we can see, the best way to treat chronic nicotine addiction from smoking is to have these Pacman-like antibodies on patrol, clearing the blood as needed before nicotine can have any biological effect."

"While we have only tested mice to date, we are very hopeful that this kind of vaccine strategy can finally help the millions of smokers who have tried to stop, exhausting all the methods on the market today, but find their nicotine addiction to be strong enough to overcome these current approaches," said Dr. Crystal. "Smoking affects a huge number of people worldwide, and there are many people who would like to quit, but need effective help. This novel vaccine may offer a much-needed solution."

Related Links:

Weill Cornell Medical College



New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Collection and Transport System
PurSafe Plus®
Capillary Blood Collection Tube
IMPROMINI M3
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: Private equity firms Blackstone and TPG have joined forces to acquire Hologic in a major healthcare deal (Photo courtesy of Hologic)

Hologic to be Acquired by Blackstone and TPG

Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.